GOALS: Cancer patients treated with chemotherapy often develop anaemia. This cross-sectional analysis examined the effect of anaemia treatment on patient and caregiver time and activities. MATERIALS AND METHODS: The analysis included 9,920 patients from 646 US outpatient oncology centres. Patients completed a survey that contained questions about travel time, total time for the visit and other impacts. RESULTS: The mean time taken for a single clinic visit to receive anaemia treatment was 2.2 h. On average, patients receiving epoetin alfa required 17.6 h more than patients receiving darbepoetin alfa to complete a course of anaemia treatment. All patients in the study reported that they had to adjust at least one activity as a result of clinic visits. Older patients, women and patients from low-income areas were more likely to be accompanied during clinic visits. CONCLUSIONS: Reducing the number of clinic visits needed for anaemia treatment by using darbepoetin alfa may benefit patients.
GOALS: Cancerpatients treated with chemotherapy often develop anaemia. This cross-sectional analysis examined the effect of anaemia treatment on patient and caregiver time and activities. MATERIALS AND METHODS: The analysis included 9,920 patients from 646 US outpatient oncology centres. Patients completed a survey that contained questions about travel time, total time for the visit and other impacts. RESULTS: The mean time taken for a single clinic visit to receive anaemia treatment was 2.2 h. On average, patients receiving epoetin alfa required 17.6 h more than patients receiving darbepoetin alfa to complete a course of anaemia treatment. All patients in the study reported that they had to adjust at least one activity as a result of clinic visits. Older patients, women and patients from low-income areas were more likely to be accompanied during clinic visits. CONCLUSIONS: Reducing the number of clinic visits needed for anaemia treatment by using darbepoetin alfa may benefit patients.
Authors: Gunnar Birgegård; Matti S Aapro; Carsten Bokemeyer; Mario Dicato; Peter Drings; Javier Hornedo; Maciej Krzakowski; Heinz Ludwig; Sergio Pecorelli; Hans Schmoll; Maurice Schneider; Dirk Schrijvers; Daniel Shasha; Simon Van Belle Journal: Oncology Date: 2005 Impact factor: 2.935
Authors: P S Houts; A Lipton; H A Harvey; B Martin; M A Simmonds; R H Dixon; S Longo; T Andrews; R A Gordon; J Meloy Journal: Cancer Date: 1984-06-01 Impact factor: 6.860
Authors: Johan Vansteenkiste; Robert Pirker; Bartomeu Massuti; Fernando Barata; Albert Font; Michael Fiegl; Salvatore Siena; Jenni Gateley; Dianne Tomita; Alan B Colowick; Jaromir Musil Journal: J Natl Cancer Inst Date: 2002-08-21 Impact factor: 13.506
Authors: Richard de Boer; Michael Clemens; Gabor Renczes; Dusan Kotasek; Jana Prausova; Norbert Marschner; Michael Hedenus; Sameer Doshi; Lisa Hendricks; Anders C Österborg Journal: Med Oncol Date: 2010-10-29 Impact factor: 3.064
Authors: David H Henry; Hema N Viswanathan; Eric P Elkin; Shana Traina; Shawn Wade; David Cella Journal: Support Care Cancer Date: 2008-01-17 Impact factor: 3.603
Authors: Patricia K Corey-Lisle; Marie-Pierre Desrosiers; Helen Collins; Margarita De La Orden; Krista A Payne; Charles Briac Levaché; Patrick Dumont Journal: Ther Adv Med Oncol Date: 2014-07 Impact factor: 8.168
Authors: Sanatan Shreay; Marie-Pierre Desrosiers; Patricia Corey-Lisle; Krista Payne Journal: Support Care Cancer Date: 2012-12-22 Impact factor: 3.603